Live Earnings Conference Call: Aytu BioPharma will host a live Q4 2026 earnings call on September 22, 2026 at 4:30PM ET. NASDAQ:AYTU Aytu BioPharma Q4 2026 Earnings Report $2.13 +0.01 (+0.47%) Closing price 09/21/2026 04:00 PM EasternExtended Trading$2.25 +0.12 (+5.45%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Live Call not available Upcoming EventEarnings Conference CallAytu BioPharma Q4 202600:00 / 00:00Live Transcript Follow Audio Aytu BioPharma EPS ResultsActual EPSN/AConsensus EPS -$0.29Beat/MissN/AOne Year Ago EPSN/AAytu BioPharma Revenue ResultsActual RevenueN/AExpected Revenue$12.28 millionBeat/MissN/AYoY Revenue GrowthN/AAytu BioPharma Announcement DetailsQuarterQ4 2026Date9/22/2026TimeAfter Market ClosesConference Call DateTuesday, September 22, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Aytu BioPharma Earnings HeadlinesContrasting Aytu BioPharma (NASDAQ:AYTU) and Harrow (NASDAQ:HROW)September 21 at 4:58 AM | americanbankingnews.comReviewing Aytu BioPharma (NASDAQ:AYTU) & Milestone Pharmaceuticals (NASDAQ:MIST)September 20 at 4:14 AM | americanbankingnews.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.September 22 at 1:00 AM | American Alternative (Ad)Aytu BioPharma (NASDAQ:AYTU) Stock Price Passes Below 50-Day Moving Average - Should You Sell?September 12, 2026 | americanbankingnews.comAytu BioPharma, Inc.: Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026May 18, 2026 | finanznachrichten.deAytu BioPharma, Inc. Q3 2026 Earnings Call SummaryMay 15, 2026 | finance.yahoo.comSee More Aytu BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aytu BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aytu BioPharma and other key companies, straight to your email. Email Address About Aytu BioPharmaAytu BioPharma (NASDAQ:AYTU), Inc. is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions. Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation. The company has also marketed other prescription and consumer health products over time, with its portfolio subject to change through acquisitions, licensing arrangements and product divestitures. The company was formed in 2015 through the merger of Aytu BioScience and Nivalis Therapeutics and is headquartered in the United States. Aytu primarily serves the U.S. healthcare market through commercial, distribution and specialty-pharmacy channels. Josh Disbrow has served as the company’s chief executive officer since its formation.View Aytu BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
